AIMEI HEALTH TECHNOLOGY CO (AFJK) Fundamental Analysis & Valuation
NASDAQ:AFJK • KYG013411098
Current stock price
56 USD
-11.86 (-17.48%)
At close:
51.0937 USD
-4.91 (-8.76%)
After Hours:
This AFJK fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. AFJK Profitability Analysis
1.1 Basic Checks
- AFJK had positive earnings in the past year.
- AFJK had a negative operating cash flow in the past year.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.09% | ||
| ROE | 3.35% | ||
| ROIC | N/A |
ROA(3y)1.23%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- AFJK does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. AFJK Health Analysis
2.1 Basic Checks
- AFJK has a worse debt/assets ratio than last year.
2.2 Solvency
- AFJK has an Altman-Z score of 71.68. This indicates that AFJK is financially healthy and has little risk of bankruptcy at the moment.
- A Debt/Equity ratio of 0.04 indicates that AFJK is not too dependend on debt financing.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 71.68 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- A Current Ratio of 0.01 indicates that AFJK may have some problems paying its short term obligations.
- A Quick Ratio of 0.01 indicates that AFJK may have some problems paying its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.01 | ||
| Quick Ratio | 0.01 |
3. AFJK Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 1388.42% over the past year.
EPS 1Y (TTM)1388.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.12%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. AFJK Valuation Analysis
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 280.00, AFJK can be considered very expensive at the moment.
- AFJK's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.78.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 280 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. AFJK Dividend Analysis
5.1 Amount
- No dividends for AFJK!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
AFJK Fundamentals: All Metrics, Ratios and Statistics
56
-11.86 (-17.48%)
Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)03-09 2026-03-09
Earnings (Next)05-01 2026-05-01
Inst Owners19.62%
Inst Owner Change0%
Ins Owners2.48%
Ins Owner Change0%
Market Cap342.72M
Revenue(TTM)N/A
Net Income(TTM)1.41M
AnalystsN/A
Price TargetN/A
Short Float %0.09%
Short Ratio0.29
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 280 | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 8.16 | ||
| P/tB | 8.16 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.2
EY0.36%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.12
FCFYN/A
OCF(TTM)-0.12
OCFYN/A
SpS0
BVpS6.86
TBVpS6.86
PEG (NY)N/A
PEG (5Y)N/A
Graham Number5.56
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.09% | ||
| ROE | 3.35% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)1.23%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.01 | ||
| Quick Ratio | 0.01 | ||
| Altman-Z | 71.68 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1388.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.12%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-3636.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A
AIMEI HEALTH TECHNOLOGY CO / AFJK Fundamental Analysis FAQ
What is the fundamental rating for AFJK stock?
ChartMill assigns a fundamental rating of 1 / 10 to AFJK.
Can you provide the valuation status for AIMEI HEALTH TECHNOLOGY CO?
ChartMill assigns a valuation rating of 0 / 10 to AIMEI HEALTH TECHNOLOGY CO (AFJK). This can be considered as Overvalued.
Can you provide the profitability details for AIMEI HEALTH TECHNOLOGY CO?
AIMEI HEALTH TECHNOLOGY CO (AFJK) has a profitability rating of 0 / 10.